Home › Research › Treatments
Lecanemab e la malattia di Alzheimer-Perusini: tra speranze terapeutiche e sfide regolatorie
Francesco Nonino, Carlo Colosimo, Luca Massacesi. Recenti Progressi in Medicina, 2025-07-01
Topic: Amyloid, tau and blood-test diagnosis
Alzheimer-Perusini's disease (AD) represents a growing health crisis. The lack of effective disease-modifying treatments and its increasing prevalence in the elderly population contribute to a major burden for patients and their caregivers, challenging health systems globally. The accumulation of beta-amyloid protein (Aβ) within the brain tissue plays an important pathogenic role in the inflammatory and degenerative mechanisms leading to cognitive and functional impairment. In recent years monoclonal antibodies targeting (Aβ) have been developed and one of them (lecanemab) recently received marketing authorization by the European Medicines Agency (Ema). Although they represent an important innovation in the treatment of AD, their clinical net benefit is uncertain, due to modest efficacy and the threat of potentially severe side effects. Cost, mode od delivery and complexity of programs aimed at minimizing risks for people with AD may limit access to these therapies and pose equity issues within health systems.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Nonino, F., Colosimo, C., & Massacesi, L. (2025). Lecanemab e la malattia di Alzheimer-Perusini: tra speranze terapeutiche e sfide regolatorie. Recenti Progressi in Medicina. https://doi.org/10.1701/4530.45309
Vancouver
Nonino F, Colosimo C, Massacesi L. Lecanemab e la malattia di Alzheimer-Perusini: tra speranze terapeutiche e sfide regolatorie. Recenti Progressi in Medicina. 2025. doi:10.1701/4530.45309. PMID: 40637522.
BibTeX
@article{nonino2025-40637522,
author = {Nonino, Francesco and Colosimo, Carlo and Massacesi, Luca},
title = {{Lecanemab e la malattia di Alzheimer-Perusini: tra speranze terapeutiche e sfide regolatorie}},
journal = {Recenti Progressi in Medicina},
year = {2025},
doi = {10.1701/4530.45309},
pmid = {40637522},
url = {https://doi.org/10.1701/4530.45309}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The lack of effective disease-modifying treatments and its increasing prevalence in the elderly population contribute to a major burden for patients and their caregivers, challenging health systems globally.
- The accumulation of beta-amyloid protein (Aβ) within the brain tissue plays an important pathogenic role in the inflammatory and degenerative mechanisms leading to cognitive and functional impairment.
- In recent years monoclonal antibodies targeting (Aβ) have been developed and one of them (lecanemab) recently received marketing authorization by the European Medicines Agency (Ema).
- Although they represent an important innovation in the treatment of AD, their clinical net benefit is uncertain, due to modest efficacy and the threat of potentially severe side effects.
- Cost, mode od delivery and complexity of programs aimed at minimizing risks for people with AD may limit access to these therapies and pose equity issues within health systems.
Why it matters
Lecanemab recently received marketing authorisation from the European Medicines Agency, an important innovation in Alzheimer disease treatment. However, its clinical net benefit is uncertain because of modest efficacy and the threat of potentially severe side effects, and cost, mode of delivery and risk-minimising programmes may limit access and raise equity issues.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 29/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Recenti Progressi in Medicina) |
| Journal's citation record | 0 / 4 | Recenti Progressi in Medicina: journal h-index 21 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Luca Massacesi: h-index 46 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Florence: institution h-index 739 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40637522) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 29 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related studies in Treatments
Also tagged “double-blind”
783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.